Posted by Michael Wonder on 15 Jun 2017
'Monumental U-turn' on cancer drug
15 June 2017 - A pioneering and life-extending drug repeatedly deemed too expensive will now be offered on the NHS in England.
It is the result of a confidential deal between the health service and the drug company Roche.
Kadcyla, the undiscounted cost of which had been £90,000 per patient, adds an average of six months of life to women with a form of terminal breast cancer.
